Trial of Covid-19 drug given via inhaler ‘very promising’, say scientists
by Niola Davis/the Guardian
Trials of an experimental drug inhaled by patients have found a significant reduction in hospital patients with Covid-19 needing to be put on a ventilator or dying from the disease, according to researchers
The drug, called SNG001, is delivered via an inhaler and is based on interferon beta, a protein produced naturally in the body that plays an important role in coordinating the body’s antiviral response.
Researchers have announced the results of an initial trial which found the odds of Covid-19 patients needing ventilation, or dying, while being treated in hospital were reduced by 79% among those given SNG001 compared with those given a placebo.
What is more, the team behind the trial say those given the drug were just over twice as likely to show “no limitation of activities” or “no clinical or virological evidence of infection” during the 16-day study period – in other words, the chance of recovery was boosted. Those given the drug also showed a reduction in breathlessness.
Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.
She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – one daughter-in-law; Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with her husband Gordon Duff, many cats, and two rescues.